DALLAS, March 13, 2025 /PRNewswire/ — Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision due to various retinal degenerative diseases, today announced that Sulagna Bhattacharya, Chief Executive Officer and Co-Founder of Nanoscope Therapeutics, will present at the H.C. Wainwright 3rd Annual BioConnect Showcase, taking place March 16-18, 2025, on Kiawah Island, SC. Details for the presentation are as follows:
Ms. Bhattacharya will provide an overview of Nanoscope and give an update on the Company’s clinical and corporate activities on Monday, March 17, at 9:40 AM Eastern Time in the Grand Oaks ballroom.
The executive team will be available to meet with investors during the event.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in H1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial, also in the first half of 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.
Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-to-present-at-the-hc-wainwright-3rd-annual-bioconnect-showcase-302401593.html
SOURCE Nanoscope Therapeutics
Disclaimer: The above press release comes to you under an arrangement with PR Newswire. We takes no editorial responsibility for the same.